BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
2/28/2020 10:08:51 AM | Browse: 771 | Download: 1125
 |
Received |
|
2019-06-22 08:09 |
|
Peer-Review Started |
|
2019-06-24 08:07 |
|
To Make the First Decision |
|
2019-08-29 00:45 |
|
Return for Revision |
|
2019-08-29 01:23 |
|
Revised |
|
2019-09-26 05:07 |
|
Second Decision |
|
2019-10-18 10:13 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2019-10-19 22:18 |
|
Articles in Press |
|
2019-10-19 22:18 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2019-11-29 22:31 |
|
Typeset the Manuscript |
|
2019-12-14 07:14 |
|
Publish the Manuscript Online |
|
2020-02-28 10:08 |
| ISSN |
2308-3840 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Meta-Analysis |
| Article Title |
Long-term efficacy of capecitabine plus oxaliplatin chemotherapy on stage III colon cancer: A meta-analysis
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Hong-Tao Fu, Jing-Jing Tian, Ying-Ying Xu, Jia-Xin Fu, Shao-Ling Nie, Yan-Yan Tang, Ping Chen and Liang Zong |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Liang Zong, PhD, Doctor, Professor, Research Associate, Department of General Surgery, Northern Jiangsu People’s Hospital, Yangzhou University, Yangzhou 225001, Jiangsu Province, China. 250537471@qq.com |
| Key Words |
Capecitabine plus oxaliplatin chemotherapy; Colon cancer; Meta-analysis; Long-term effect; ; |
| Core Tip |
Many clinical studies for the long-term survival or efficacy of capecitabine plus oxaliplatin (XELOX) in colon cancer have already been studied, but its clinical benefit is controversial. The long-term efficacy of XELOX regimen in comparison with other adjuvant chemotherapy protocols in colon cancer was evaluated. By searching the PubMed, Embase and Cochrane, a total of 12 randomized controlled trials involving 6698 stage III colon cancer cases were included. Our findings pointed that XELOX regimen showed a better OS and a better disease-free survival. The XELOX regimen can be a preferred option for adjuvant treatment of stage III colon cancer after surgery. |
| Publish Date |
2020-02-28 10:08 |
| Citation |
Fu HT, Tian JJ, Xu YY, Fu JX, Nie SL, Tang YY, Chen P, Zong L. Long-term efficacy of capecitabine plus oxaliplatin chemotherapy on stage III colon cancer: A meta-analysis. World J Meta-anal 2020; 8(1): 27-40 |
| URL |
https://www.wjgnet.com/2308-3840/full/v8/i1/27.htm |
| DOI |
https://dx.doi.org/10.13105/wjma.v8.i1.27 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
